PE20210948A1 - Moduladores del receptor nmda heteroaromatico y usos de los mismos - Google Patents

Moduladores del receptor nmda heteroaromatico y usos de los mismos

Info

Publication number
PE20210948A1
PE20210948A1 PE2021000151A PE2021000151A PE20210948A1 PE 20210948 A1 PE20210948 A1 PE 20210948A1 PE 2021000151 A PE2021000151 A PE 2021000151A PE 2021000151 A PE2021000151 A PE 2021000151A PE 20210948 A1 PE20210948 A1 PE 20210948A1
Authority
PE
Peru
Prior art keywords
heteroaromatic
receiver modulators
nmda
nmda receiver
modulators
Prior art date
Application number
PE2021000151A
Other languages
English (en)
Inventor
Robert A Volkmann
David R Anderson
Sam Malekiani
Timothy PISER
Gregg F Keaney
Steven C Leiser
Original Assignee
Cadent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadent Therapeutics Inc filed Critical Cadent Therapeutics Inc
Publication of PE20210948A1 publication Critical patent/PE20210948A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Se proporciona 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1- il)-2-oxoetil)-3,7-dihidro-4H-pirrolo[2,3-d]pirimidin-4-ona y sus sales farmaceuticamente aceptables, y sus usos en el tratamiento de trastornos psiquiatricos, neurologicos y del neurodesarrollo, asi como enfermedades del sistema nervioso.
PE2021000151A 2018-08-03 2019-08-02 Moduladores del receptor nmda heteroaromatico y usos de los mismos PE20210948A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862714100P 2018-08-03 2018-08-03
PCT/US2019/044814 WO2020086136A2 (en) 2018-08-03 2019-08-02 Heteroaromatic nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
PE20210948A1 true PE20210948A1 (es) 2021-05-24

Family

ID=69228330

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000151A PE20210948A1 (es) 2018-08-03 2019-08-02 Moduladores del receptor nmda heteroaromatico y usos de los mismos

Country Status (36)

Country Link
US (3) US10584131B2 (es)
EP (2) EP3830092B1 (es)
JP (1) JP7319369B2 (es)
KR (1) KR20210039432A (es)
CN (1) CN112513047B (es)
AR (1) AR115905A1 (es)
AU (1) AU2019368147A1 (es)
BR (1) BR112021001967A2 (es)
CA (1) CA3108519A1 (es)
CL (1) CL2021000294A1 (es)
CO (1) CO2021002898A2 (es)
CR (1) CR20210125A (es)
CU (1) CU24647B1 (es)
CY (1) CY1126144T1 (es)
DK (1) DK3830092T3 (es)
DO (1) DOP2021000025A (es)
EA (1) EA202190431A1 (es)
EC (1) ECSP21014902A (es)
ES (1) ES2951872T3 (es)
FI (1) FI3830092T3 (es)
HR (1) HRP20230774T1 (es)
HU (1) HUE062566T2 (es)
IL (1) IL280474B2 (es)
JO (1) JOP20210020A1 (es)
LT (1) LT3830092T (es)
MA (1) MA53351B1 (es)
MX (1) MX2021001367A (es)
PE (1) PE20210948A1 (es)
PH (1) PH12021550242A1 (es)
PL (1) PL3830092T3 (es)
PT (1) PT3830092T (es)
RS (1) RS64359B1 (es)
SG (1) SG11202101125VA (es)
SI (1) SI3830092T1 (es)
WO (1) WO2020086136A2 (es)
ZA (1) ZA202101273B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3386591T (lt) * 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
WO2017100593A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
HUE062566T2 (hu) 2018-08-03 2023-11-28 Novartis Ag Heteroaromás NMDA receptor modulátorok és alkalmazásaik

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
FR2549834B1 (fr) 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
US5298502A (en) 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
AU6643694A (en) 1993-05-21 1994-12-20 Pentapharm Ag 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones
JP2000513375A (ja) 1996-06-28 2000-10-10 メルク エンド カンパニー インコーポレーテッド フィブリノーゲンレセプター拮抗薬プロドラッグ
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
CA2412640A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CN101035765B (zh) 2004-07-13 2010-10-13 弗·哈夫曼-拉罗切有限公司 磺酰胺衍生物
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
AU2007296634B2 (en) 2006-09-11 2012-09-20 Merck Sharp & Dohme B.V. Quinazolinone and isoquinolinone acetamide derivatives
MX2009002685A (es) 2006-09-11 2009-10-13 Organon Nv Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il).
US7858782B2 (en) 2006-12-15 2010-12-28 Abraxis Bioscience, Llc Triazine derivatives and their therapeutical applications
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
US8183276B2 (en) 2007-02-08 2012-05-22 Christian Fischer Therapeutic agents
WO2008128982A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
CA2685753A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
US8653059B2 (en) 2007-08-21 2014-02-18 Merck Sharp & Dohme Corp. Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
CA2723135A1 (en) 2008-05-01 2009-11-05 Sirtris Pharmaceuticals, Inc. Quenolines and related analogs as sirtuin modulators
KR20110019385A (ko) 2008-05-29 2011-02-25 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 이미다조피리딘 및 관련 유사체
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
WO2010003048A1 (en) 2008-07-03 2010-01-07 Sirtris Pharmaceuticals, Inc. Benzimidazoles and related analogs as sirtuin modulators
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
MX2011003373A (es) 2008-09-29 2011-06-09 Sirtris Pharmaceuticals Inc Quinazolinona, quinolona y analogos relacionados como moduladores de sirtuina.
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
ES2540119T3 (es) 2009-03-27 2015-07-08 Abbvie Inc. Compuestos como ligandos de receptores cannabinoides
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
IN2012DN02968A (es) 2009-10-13 2015-07-31 Msd Oss Bv
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
WO2011117381A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
CA2805724A1 (en) 2010-07-16 2012-01-19 Rockefeller University Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9115096B2 (en) 2011-05-10 2015-08-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8993557B2 (en) 2011-09-30 2015-03-31 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
EP2760840B1 (en) 2011-09-30 2015-08-12 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
CN104105485B (zh) 2011-11-11 2017-04-12 吉利德阿波罗公司 Acc抑制剂和其用途
TR201813877T4 (tr) 2012-02-10 2018-11-21 Hoffmann La Roche Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
US9278973B2 (en) 2012-10-25 2016-03-08 Bioenergenix Llc Heterocyclic compounds for the inhibition of PASK
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
NZ716392A (en) 2013-06-28 2017-03-31 Beigene Ltd Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201609656A (zh) 2013-09-26 2016-03-16 美涅莫辛製藥公司 Ｎｒ２ａ之ｎ-芳基甲基磺醯胺負向調節劑
ES2690355T3 (es) 2013-10-11 2018-11-20 F. Hoffmann-La Roche Ag Tiazolopirimidinonas como moduladores de la actividad del receptor de NMDA
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
EP3191459A1 (en) 2014-09-05 2017-07-19 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US20170313719A1 (en) 2014-11-18 2017-11-02 Emory University Thieno[2,3-D]pyrimidin-4-one Derivatives as NMDAR Modulators and Uses Related Thereto
AU2016248886B2 (en) 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators
BR112018007681A2 (pt) 2015-10-16 2018-11-06 Univ Northwestern combinação farmacêutica de um antipsicótico atípico e um modulador de nmda para o tratamento de esquizofrenia, distúrbio bipolar, comprometimento cognitivo e distúrbio depressivo maior
LT3386591T (lt) 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
WO2017100593A1 (en) 2015-12-09 2017-06-15 Luc Therapeutics Thienopyrimidinone nmda receptor modulators and uses thereof
US20170305861A1 (en) 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
US11186564B2 (en) 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
RS62872B1 (sr) 2017-09-27 2022-02-28 Incyte Corp Soli derivata pirrolotriazina korisne kao tam inhibitori
HUE062566T2 (hu) 2018-08-03 2023-11-28 Novartis Ag Heteroaromás NMDA receptor modulátorok és alkalmazásaik
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor

Also Published As

Publication number Publication date
ZA202101273B (en) 2023-05-31
JP2021534227A (ja) 2021-12-09
PT3830092T (pt) 2023-07-25
DK3830092T3 (en) 2023-08-07
SG11202101125VA (en) 2021-03-30
DOP2021000025A (es) 2021-05-31
WO2020086136A2 (en) 2020-04-30
HUE062566T2 (hu) 2023-11-28
MX2021001367A (es) 2021-06-23
US20200131190A1 (en) 2020-04-30
CO2021002898A2 (es) 2021-05-31
FI3830092T3 (fi) 2023-07-21
IL280474B2 (en) 2023-09-01
MA53351B1 (fr) 2023-08-31
HRP20230774T1 (hr) 2023-10-27
IL280474B1 (en) 2023-05-01
AR115905A1 (es) 2021-03-10
EP4223760A1 (en) 2023-08-09
JOP20210020A1 (ar) 2021-01-25
US20200039987A1 (en) 2020-02-06
CN112513047B (zh) 2023-10-20
RS64359B1 (sr) 2023-08-31
SI3830092T1 (sl) 2023-09-29
CL2021000294A1 (es) 2021-06-18
CU24647B1 (es) 2023-02-13
JP7319369B2 (ja) 2023-08-01
TW202019932A (zh) 2020-06-01
AU2019368147A1 (en) 2021-03-18
BR112021001967A2 (pt) 2021-04-27
CN112513047A (zh) 2021-03-16
ES2951872T3 (es) 2023-10-25
WO2020086136A3 (en) 2020-08-06
LT3830092T (lt) 2023-09-11
US10752633B2 (en) 2020-08-25
EP3830092A2 (en) 2021-06-09
US10584131B2 (en) 2020-03-10
ECSP21014902A (es) 2021-05-31
CA3108519A1 (en) 2020-04-30
US20210403474A1 (en) 2021-12-30
IL280474A (en) 2021-03-01
CR20210125A (es) 2021-06-30
CU20210013A7 (es) 2021-09-07
PH12021550242A1 (en) 2021-11-29
EA202190431A1 (ru) 2021-06-11
US11542264B2 (en) 2023-01-03
MA53351A (fr) 2022-01-12
EP3830092B1 (en) 2023-05-03
KR20210039432A (ko) 2021-04-09
CY1126144T1 (el) 2023-11-15
PL3830092T3 (pl) 2023-11-13

Similar Documents

Publication Publication Date Title
PE20210948A1 (es) Moduladores del receptor nmda heteroaromatico y usos de los mismos
EA201791239A1 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
CL2019000882A1 (es) Sustituto de 1h-imidazo[4,5-b]piridina-2(3h)-ones y sus uso como moduladores de receptor glun2b.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
MA53835A (fr) Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
MX2020000690A (es) Compuestos heterociclicos como antagonistas de adenosina.
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2013003051A1 (es) Compuestos derivados de pirazolo (4.3-d) pirimidinas, inhibidores de quinasa; composicion farmaceutica; y uso para el tratamiento de enfermedades y trastornos del aparato respiratorio
EP3429605A4 (en) THERAPEUTIC AGENT FOR THE TREATMENT OF DISEASES, IN PARTICULAR DISEASES AFFECTING THE CENTRAL NERVOUS SYSTEM
ECSP18093944A (es) 1H-Pirazolo[4,3-b]piridinas como inhibidores de PDE1
DOP2014000039A (es) Inhibidores de pde10 de pirimidina
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
PH12018500627A1 (en) Compounds and compositions for the treatment of ocular disorders
MX2020000693A (es) Compuestos de 1,8-naftiridinona, y usos de los mismos.
CL2008003362A1 (es) Compuestos heterociclos derivados de tieno(2,3-d)pirimidinona, con actividad estimuladora del receptor ampa; composicion farmaceutica; y uso de los compuestos en el tratamiento de afecciones siquiatricas tales como esquizofrenia, depresion y trastornos del aprendizaje.
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
MX2020004148A (es) Sales cristalinas de un inhibidor de cinasa de fibrosarcoma acelerado rapidamente (b-raf).
EA201692250A1 (ru) Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций
CL2021001547A1 (es) Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer
EA201892724A1 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ